Abbvie Inc ABBV

$259.93 -1.66 (-0.63%)

Valuation

Market cap
465,178,912,000
Revenue TTM
$61,160,000,000
Net income TTM
$4,226,000,000
PE ratio
24.50
Forward PE
18.95
Profit margin
6.91%
Debt to equity
-12.03

Trading

Volume
3,892,076
Avg volume
4,643,904
Day's range
$259.00 – $262.32
Shares out
1,766,793,000
Stochastic %K
4%
Beta
0.29
Analysts
Strong Sell
Price target
$278.20

Price

Company profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to...

Show more

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
847 932 7900
Website
https://www.abbvie.com
Address
1 North Waukegan Road, North Chicago, United States

Latest news

Stocktwits

topstockalerts Oct 1, 11:48 PM
ADARx Pharmaceuticals announced that underwriters fully exercised their option to purchase an additional 3,937,500 common shares at $17 per share, with the transaction closing October 1, 2026. The exercise brings total shares sold in the company’s IPO to 30.1875 million, generating approximately $513.2 million in gross proceeds before underwriting discounts, commissions and offering expenses. Separately, AbbVie purchased 5,255,542 ADARx shares at $17 per share through a concurrent private placement. Including the IPO, ADARx raised approximately $602.5 million in total gross proceeds before fees and expenses. The additional capital significantly expands ADARx’s funding base as it advances its pharmaceutical development programs. J.P. Morgan, Morgan Stanley, TD Cowen and UBS Investment Bank served as lead book-running managers, with LifeSci Capital acting as an additional bookrunner. $ADRX $ABBV
0 replies
Quantumup Oct 1, 6:24 PM
H.C. Wainwright reiterated $SNDX Buy; PT $38 $KURA $ABBV - RHHBY OTSKY BMY INCY AVLN SNY H.C. Wainwright said in its note: Ahead of 3Q earnings, we completed a deeper diligence effort around NPM1m AML biology and market dynamics that provides a granular understanding of the unique headwinds and underappreciated opportunities within R/R NPM1m AML. Our work centered on revisiting commercial assumptions for the NPM1m AML market as compared to KMT2Ar. We spoke to leading hematologist-oncologists to gain a quick perspective on how targeted therapies like Revuforj are being integrated into existing treatment algorithms, and how those protocols diverge between different genetic subsets of AML in both the frontline and R/R setting. Overall, we came away with a nuanced view of the NPM1m market where frequent actionable co-mutations create headwinds from established targeted therapies in treatment sequencing, rather than from menin inhibitors.
0 replies
55X_ROI_Q1_2026 Oct 1, 4:55 PM
$SLS $MRNA • Phase 3 Results are overdue - and Incoming any day now. and while we are seeing Miraculous Survival in this P3 Trial, Aza+ven - BAT for Control Patients has FAILED 5 AML Trials - Including 2 Phase 3 Trials for AML Remission Maintenance $ABBV Verona P3 Failed • VIALE-M FAILED - AML First Remission (CR1) Maintenance - FAILED • VIALE-T FAILED - AML Post Transplant Maintenance Terminated Paradigm FAILED to Increase OS Opti-AML FAILED to Increase OS --- it ain't BAT - it's not complicated - its Gps doing what its done in ALL Prior Trials, Prevent Relapse and extend Survival - Including in 2 Phase 2 trials for AML Remission.
0 replies
DidYouReadThis Oct 1, 4:00 PM
Most likely to #acquire biggest number of #biotechs in 2027? $NVS $ABBV $LLY $JNJ
0 replies
Quantumup Oct 1, 12:33 PM
JPMorgan🏁 $SYRE and said -- We are initiating coverage of Spyre Therapeutics (SYRE) with an Overweight rating and a $110 year-end 2027 price target. PTGX - $JNJ $ABBV LLY PFE BMY MRK ABVX TEVA - SNY TAK SYBX RHHBY Here's what JPMorgan went on to say: https://x.com/Quantumup1/status/2105637128470192546?s=20
0 replies
focafoca99 Oct 1, 12:14 PM
$ABBV prepares to host its Q3 2026 earnings call on Oct 30 before market open. https://www.rapidticker.com/news/abbv-abbvie-to-host-third-quarter-5a6f88
0 replies
SellasgpsCurativeBAT11 Sep 30, 5:33 PM
$ABBV $BMY $JNJ $PFE $SLS Pfizer CEO Dr. Bourla friend of Sellas CEO Dr. Stergiou. Dr. Bourla Cancer is not one disease. It hides, it adapts, it comes back different. That is why the research is so complicated, and why it has remained the greatest challenge in medicine. But the science is breaking, and we can now see opportunities to defeat it that we could not even dream of a few years ago. Going after a problem that big takes focus, and the same is true for all of us, whatever your goal may be. Focus enables ambition. When it is guided by real purpose, you can go further than you ever thought possible. That is why we dedicate the greatest share of our research to cancer, and why I am more optimistic than ever about what that will mean for patients. On #WorldCancerResearchDay, my thanks to every researcher working to get us there. ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Sep 30, 4:36 PM
$ABBV $BMY $JNJ $PFE $SLS 4 of the most powerful companies in oncology all have specific strategic reasons to own GPS after a positive REGAL readout. BMS needs to protect Onureg. AbbVie needs to protect Venetoclax. Merck needs to extend Keytruda past the patent cliff. And Pfizer just hired people who came from the exact companies that GPS is about to disrupt and know precisely what that disruption is worth. ✌️🙏❤️‍🩹
1 replies